Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Giuseppe LambertiLisa ManuzziIlaria MaggioDavide CampanaPublished in: Journal of surgical oncology (2020)